Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. (NUS) Market Cap

Nu Skin Enterprises, Inc. has a market capitalization of $252M.

Price: $5.19

-0.04 (-0.76%)

Market Cap: 251.98M

NYSE · time unavailable

CEO: Ryan S. Napierski

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1996-11-22

Website: https://www.nuskin.com

Nu Skin Enterprises, Inc. (NUS) - Company Information

Market Cap: 251.98M|Sector: Consumer Defensive

Company Profile

Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items. In the realm of health and nutrition, Nu Skin provides a comprehensive array of dietary and weight management products. This includes ageLOC Youth, LifePak, and ageLOC Meta nutritional supplements, in addition to ageLOC TR90 programs designed for weight control and body contouring, Beauty Focus Collagen+ skin care supplements, and other related weight management aids. The organization also significantly invests in research and development, particularly for its skincare and nutritional supplement portfolios. Nu Skin operates a network of retail stores and customer service centers exclusively within Mainland China. Its extensive product lines are marketed under its proprietary brands, which include Nu Skin, Pharmanex, and ageLOC. These products reach consumers through multiple sales channels, including direct-to-consumer interactions, an extensive network of independent distributors, and its dedicated e-commerce platform. Nu Skin Enterprises, Inc. was established in 1984 and maintains its corporate headquarters in Provo, Utah.

Analyst Sentiment

60%
Buy

From 0 Active Polls

1Y Forecast: $11.00

▲ +111.9% Potential Upside

Consensus Target Metrics

Low Bound

$11

Median

$11

High Bound

$11

Average

$11

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$11.00
▲ +111.95% Upside
Low Target
$11.00
112% Risk
Median Target
$11.00
112% Mid
High Target
$11.00
112% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 NU SKIN ENTERPRISES INC CLASS A (NUS) — Investment Overview

🧩 Business Model Overview

Nu Skin operates a direct-selling model for personal care and beauty products, selling primarily through a network of independent sales representatives. The value chain centers on (1) product development and supply sourcing, (2) marketing and education provided to the distributor network, and (3) repeat purchasing driven by customer and distributor engagement programs. Unlike traditional retail, the company’s commercial infrastructure is distributed: product discovery, replenishment, and customer acquisition are heavily enabled by ongoing interpersonal selling and brand education delivered through the independent channel.

In this model, stickiness derives from relationship depth within the distributor-to-customer ecosystem and from the operational effort required to replicate comparable product education, merchandising, and localized compliance practices across markets.

💰 Revenue Streams & Monetisation Model

Revenue is generated primarily from product sales to customers and distributors (with sales typically flowing through the independent channel rather than through company-owned stores). Monetisation is supported by:

  • Repeat purchasing behavior: personal care and beauty categories naturally support replenishment cycles, which can translate into recurring demand when customers maintain ongoing consumption habits.
  • Volume-linked distributor economics: distributor incentives are structured around sales performance, which supports continued customer solicitation and inventory movement through the network.
  • Mix and margin discipline: gross margin and operating leverage depend on product mix (premium skincare/supplements versus commoditized SKUs), promotional intensity, freight and logistics efficiency, and inventory management.

Margin drivers generally hinge on (1) stable unit demand that absorbs fixed SG&A, (2) product sourcing and manufacturing cost control, and (3) the company’s ability to maintain pricing power and reduce channel friction (including chargebacks/returns risk where applicable).

🧠 Competitive Advantages & Market Positioning

Nu Skin’s moat is best characterized as a combination of network effects and intangible assets, reinforced by switching costs created by relationship- and routine-based purchasing.

Moat mechanics:

  • Network effects (two-sided engagement): A larger and more active distributor base increases product education capacity, lowers the effective customer acquisition cost, and improves distributor recruitment prospects—supporting continued channel utilization.
  • Switching costs: Customers often buy through a trusted representative and follow regimen-based product routines; shifting to competitors requires rebuilding trust, finding new product guidance, and restarting routines.
  • Intangible assets: long-standing product know-how, formulation/ingredient expertise, and distribution/market-access capabilities are difficult to replicate quickly across regions.

Competitive benchmarking:

  • Herbalife (HLF): competes in nutrition and personal care via a similar direct-selling framework. Nu Skin’s industry focus skews more toward premium skincare and beauty positioning, while Herbalife has a heavier nutrition-centric portfolio emphasis.
  • Amway (Alticor): broad wellness and household ecosystem with large scale and extensive channel reach. Amway benefits from scale economics across categories; Nu Skin competes by leaning into a narrower beauty/personal care focus and specialist product education.
  • Avon (Altice/Avon-branded channel) (and peer direct sellers like Mary Kay): competes in beauty through representative networks. Nu Skin differentiates through its product formulation/beauty regimen positioning and direct-selling program design tailored to its specific customer base.

Relative to these rivals, the competitive challenge for entrants is not only product development—it is the build-out of compliant, market-specific distribution systems that can sustain training depth, customer education, and repeat purchase economics over time.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is most plausibly driven by secular tailwinds that benefit direct-selling ecosystems and by selective expansion in reachable geographies and channels:

  • Global demand for skincare and personal care: aging demographics, rising discretionary spend in emerging markets, and increasing consumer emphasis on appearance/skin health support category expansion.
  • Distributor productivity and retention: improving training, tools, and sales enablement can raise output per active representative and stabilize customer cohorts, supporting a more durable revenue base.
  • Digital and hybrid selling enablement: supplementing traditional relationship-based selling with digital workflows can improve customer engagement and reduce acquisition costs, supporting higher conversion and repeat rates.
  • Portfolio optimization: shifting toward higher-margin SKUs and bundling regimen-based consumption can strengthen gross margin and increase lifetime value.
  • Market expansion within regulatory constraints: sustainable growth requires careful compliance execution, leveraging the company’s existing know-how in localized product registration and channel governance.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: direct-selling practices face scrutiny related to marketing claims, territory rules, and incentive program governance. Product ingredient and labeling compliance also varies by market.
  • Channel concentration and distributor churn: revenue performance can be sensitive to representative attrition, productivity swings, and the ability to recruit and retain sales leaders.
  • Reputational and consumer-safety risk: adverse events tied to product quality, labeling accuracy, or substantiation of claims can create costly remediation and harm demand.
  • Competitive intensity: well-capitalized direct sellers and large incumbents can pressure pricing and promotional budgets, reducing margin headroom.
  • Supply chain and inventory risk: demand forecasting errors can lead to higher inventory levels, promotional write-downs, and cash flow pressure.
  • Foreign exchange and macro sensitivity: revenue from international markets can be exposed to currency movements and consumer discretionary cycles.

📊 Valuation & Market View

Equity markets often value direct-selling and consumer-oriented businesses using a blend of price-to-sales (P/S) and EV/EBITDA, with fundamentals anchored to revenue durability, distributor productivity, and operating margin sustainability. Key variables that typically move valuation include:

  • Revenue growth quality: evidence that growth is supported by repeat purchasing and healthy channel velocity rather than short-term promotions.
  • Gross margin resilience: product mix, sourcing efficiency, and promotional intensity.
  • Operating leverage: the degree to which operating expenses scale with distributor output without requiring proportionate spend increases.
  • Channel health: active representative base trends, retention, and the sustainability of recruitment.
  • Regulatory overhang: changes in marketing claim standards and enforcement intensity can affect both revenue and cost structure.

🔍 Investment Takeaway

Nu Skin’s long-term investment case rests on a structurally sticky direct-selling ecosystem. The company’s differentiating assets are relationship-driven switching costs, engagement-driven network effects, and developed intangible capabilities in product education and compliant distribution execution. While competition and regulatory scrutiny remain persistent, the durability of customer routines and distributor productivity can support a resilient revenue base and margin discipline when channel governance and portfolio optimization are executed effectively.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"NUS reported Q1 2026 revenue of $320.6M and net income of $1.84M (EPS $0.04). On a YoY basis, revenue fell (Q1 2026: -11.99% vs Q1 2025), while net income declined sharply (Q1 2026: -98.29% vs Q1 2025). QoQ, revenue decreased (Q1 2026: -13.41% vs Q4 2025) and net income also fell (Q1 2026: -87.30%). Profitability deteriorated meaningfully: gross margin was 66.9% in Q1 2026 versus 70.7% in Q4 2025, while operating margin collapsed to 1.26% (from 6.28% in Q4). Net margin dropped to 0.57% from 3.91% QoQ, indicating cost leverage and/or demand softness. Cash flow quality weakened as operating cash flow was -$3.9M and free cash flow was -$17.6M in Q1 2026, contrasting with positive operating and free cash flow in prior quarters. Balance sheet liquidity remains adequate: cash and equivalents were $198.7M and total equity was $794.1M, broadly stable QoQ. The company repurchased shares (-$5.0M) and paid dividends (-$2.9M) in the quarter. Shareholder returns look strong due to market momentum: the stock is up 40.82% over the last year (dividend yield ~0.8% noted from ratios), driving total return even though earnings have weakened."

Revenue Growth

Caution

Revenue declined QoQ (-13.41%) and YoY (-11.99%), suggesting contracting demand or weaker volume/pricing.

Profitability

Neutral

Margins contracted materially: operating margin fell to 1.26% from 6.28% QoQ; net margin fell to 0.57% from 3.91% QoQ. Net income YoY declined -98.29%.

Cash Flow Quality

Neutral

Q1 2026 operating cash flow was -$3.9M and free cash flow was -$17.6M, deteriorating versus prior quarters’ positive cash generation.

Leverage & Balance Sheet

Neutral

Liquidity is supported (cash $198.7M) and equity is stable ($794.1M). Net debt was lower QoQ ($79.0M vs $125.6M), indicating improving resilience.

Shareholder Returns

Good

Strong price momentum with 1y_change of +40.82%. Dividend yield is modest (~0.8%), and buybacks/dividends were still executed in Q1.

Analyst Sentiment & Valuation

Caution

Price target consensus is ~$11 versus current price ~$7.90 (upside implied), but the underlying earnings and cash flow trend have weakened, tempering conviction.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Nu Skin’s Q1 2026 results were largely in line with expectations, with revenue of $320.6M (1% favorable FX) and adjusted EPS of $0.14 in guidance. Margin performance was mixed: consolidated adjusted gross margin was essentially flat (67.9% vs 67.8%), but core Nu Skin gross margin improved by 20 bps to 76.9% while operating leverage weakened (adjusted operating margin fell to 3.6% from 6.4%). Investment and cost mix were the drag, including higher selling expense as they enhance compensation to drive leader productivity. The core growth narrative centers on Prysm iO adoption: subscription volume rose 5% YoY and subscribers rose to 14% of total customers, signaling improving lifetime value potential. Management is also progressing Tru Face rollout in Mainland China. Outlook is cautious but steady—Q2 guidance calls for $330M–$360M revenue and EPS $0.15–$0.25, and annual guidance is maintained while tariff/fuel inflation risks are monitored. Sentiment is mixed: “green shoots” exist, but margin and macro uncertainty persist.

AI IconGrowth Catalysts

  • Prysm iO rollout progression and leader adoption shift from product demonstration to ongoing consultative household wellness device positioning
  • Early subscription traction: subscription volume +5% YoY and subscribers as % of total customers +14% YoY, supporting higher customer lifetime value over time
  • Tru Face anti-aging product rollout in Mainland China driving improving leader engagement and demand momentum
  • Prysm-certified nutrition ecosystem strength: products certified to raise Prysm iO score outperforming total product sales
  • LifePak flagship growth: grew >10% YoY

Business Development

  • Team Elite trip next week in South Africa with top global sales leaders (alignment/learning platform tied to sales force execution)
  • Pre-market entry foundation in India with planned formal launch by end of 2026 (no named partner disclosed; operational infrastructure build-out referenced)
  • Prysm iO leader training certification program noted as primarily in Asia (Japan, Korea, China) with certifications being expanded to other markets using best practices

AI IconFinancial Highlights

  • Revenue: $320.6M, within guidance range; 1% favorable foreign currency impact
  • GAAP EPS: $0.04; Adjusted EPS: $0.14 excluding costs related to winding down the separate BeautyBio business and other charges; Adjusted EPS in line with guidance range
  • Adjusted gross margin: 67.9% vs 67.8% prior year (stable overall mix); Core Nu Skin gross margin: 76.9% up 20 bps YoY
  • Selling expense: 34.3% of revenue vs 32.5% prior year; Core Nu Skin selling expense: 40.5% up from 38.7% YoY
  • G&A: 29.9% of revenue vs 28.9% prior year; GAAP-to-adjusted narrative indicates $9M YoY decline in adjusted G&A dollars, but as a % increased due to investment and revenue context
  • Adjusted operating margin: 3.6% down from 6.4% prior year
  • Sequential guidance expectation for Q2: revenue $330M–$360M; EPS $0.15–$0.25
  • Macro/tariff and fuel-price pressures flagged as possible inflationary risk to consumer sentiment; management stated no significant guidance impact currently anticipated

AI IconCapital Funding

  • Returned approx. $8M to shareholders in Q1: $3M dividends and $5M share repurchases
  • Remaining under repurchase authorization: $137.3M at quarter end
  • Refinanced credit facilities during the quarter: extended maturities through 2031 and improved cost of borrowing; proceeds used to repay existing indebtedness (debt level not explicitly quantified in transcript)
  • Liquidity posture emphasized as strong; debt paydown expected as priority using new facility

AI IconStrategy & Ops

  • Prysm iO adoption strategy: shifting leader usage from product demo to household wellness device concept, creating near-term switching costs (leader capability build, tool integration, and engagement model change)
  • AI integration into Prysm iO: current AI supports scoring, data comparisons, personalized product recommendations; future platform introductions expected to deliver deeper insights and more actionable experiences
  • Operational efficiency and gross margin approach: localized manufacturing, portfolio optimization, and strategic pricing actions to sustain gross margin amid uncertain trade practices
  • Cost controls: disciplined G&A management while optimizing selling expense to reward sales leaders for growth; selling expense core expected ~40% for Q2
  • Emerging market expansion: refining sales compensation structures for localized entrepreneurial segments (Latin America example cited) and building infrastructure for Southeast Asia, China expansion, and India pre-launch activities

AI IconMarket Outlook

  • Annual guidance maintained; management expects to provide more clarity following Q2
  • Q2 2026 outlook: revenue $330M–$360M (assuming neutral FX); EPS $0.15–$0.25
  • India: planned formal launch by end of 2026; management stated not forecasting significant India revenue in current guide and expects ramp year-by-year following learning phase

AI IconRisks & Headwinds

  • Macro uncertainty pressuring consumers and supply chains; tariffs and trade practice uncertainty referenced as having placed significant pressures over past many years on gross margin
  • Inflationary pressures from tariffs, recent fuel price increases, and geopolitical dynamics; management is monitoring for prolonged oil/macro effects
  • Operating margin dilution: adjusted operating margin down to 3.6% from 6.4% YoY amid selling/G&A mix changes and investment
  • Near-term switching costs from Prysm iO business model transition (leader behavior change, new capabilities, and tool integration)

Q&A: Analyst Interest

  • Topic: Prysm iO training criteria for leaders and what drives higher conversion. Management described leaders that use Prysm as a consultative wellness assessment tool converting best. Training components included device/carotenoid product knowledge, consumer scan journey behavior, CRM persistency, and a train-the-trainer certification approach spanning Asia (Japan, Korea, China).
  • Topic: India growth aggressiveness, incentive changes, and timing to formal launch. Management framed India as mid-to-long-term and importance for getting it right via a roughly year-long premarket entry. They emphasized learning about Indian consumer/entrepreneur behavior, manufacturing/logistics/distribution/product formulas, and guided conservatively with low/no near-term revenue.
  • Topic: Capital allocation priorities amid buybacks/dividends and refinancing. Management maintained unchanged priorities: fund the business, invest in strategic customer/sales-leader opportunities, and preserve strong liquidity. They highlighted extending liquidity through refinancing to 2031 and indicated continued debt paydown focus alongside returning value via dividends and repurchasing shares when appropriate.

Sentiment: MIXED

Note: This summary was synthesized by AI from the NUS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for NUS.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (NUS)

© 2026 Stock Market Info — Nu Skin Enterprises, Inc. (NUS) Financial Profile